Arpida re-aligns activities to support transition of its research portfolio
Arpida Ltd. announced the cessation of its research activities in Denmark. Arpida A/S, the Danish subsidiary of Arpida Ltd., has primarily focused on hit-to-lead chemistry to support exploratory research. The cessation of these activities in Arpida A/S will lead to an overall reduction of the headcount in Research by up to 18, representing up to 25% of the company's Research unit.
Arpida's research operations, including rational drug design and chemistry, will continue at its corporate headquarters in Reinach, Switzerland. This strategic re-alignment shall bring about the appropriate concentration, integration and re-focusing of resources required for an efficient transition of the most advanced research compounds into development.
In financial terms, the refocusing operation will lead to a non-cash impairment of tangible and intangible assets of approximately CHF 1.2 million and CHF 6.1 million, respectively. These charges will be included in the 2006 accounts. The operation is expected to be completed in the second quarter of 2007.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
While not necessarily reality, perception can cause reality to evolve
Epigenomics Signs Distribution Deal with Pronto Diagnostics for Epi proColon in Israel - Epigenomics expands commercial reach for CE-marked product beyond home market
Paracetamol study could open door for way to treat liver damage
Draupnir Bio completes €12 million seed round - Development of oral small molecule degraders of extracellular proteins
Hope for first blood test to detect deadly heart inflammation - £50 blood test could improve diagnosis of myocarditis and help patients get lifesaving treatment earlier
Can loss of smell be repaired?
The_New_Zealand_Medical_Journal
Use of low-energy electrons for innovative biotechnology processes
